First-time-in-human study of CMX521 for treatment and/or prevention of norovirus infection
Phase of Trial: Phase I
Latest Information Update: 12 Jun 2018
At a glance
- Drugs CMX-521 (Primary)
- Indications Norovirus infections
- Focus Adverse reactions; First in man; Pharmacokinetics
- 12 Jun 2018 According to a Chimerix media release, study results are expected to be reported in the second half of 2018.
- 07 May 2018 According to a Chimerix media release, the company is completing the fourth cohort in the single ascending dose part of ti study and oral presentation will be presented at the International Conference on Antiviral Research (ICAR) in June 2018.
- 05 Jan 2018 According to a Chimerix media release, study results are expected in mid-2018.